Skip to main content
Equibles
PROK logo

PROK · Prokidney Corp.

Track PROK — free

Use PROK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PROK

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.33 -0.08 (-5.34%) At close · Aug 14
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least 12 months from the date these financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$402.09M
Shares
302.32M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.33 Open$1.41 Day$1.30–1.41 52W close$1.33–3.30 Avg vol 30d1.1M Short int20.7M · 6.8% float · 22.4d Short vol85% Last earningsMay 10, 2024 DataJun 2021–Aug 2026 Filing10-Q · Aug 10

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −34%
below
Price vs 50-day avg −21%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −18%
trailing
6-month return −38%
trailing
YTD return −41%
this year
Relative strength −52%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.85% of float · ▼ -1.0% MoM · 22.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
71 holders — near 1-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Strong
Revenue growth +1075%
Y/Y
Free cash flow $-135.3M
Balance sheet $108.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −60%
past year
ATR 8.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−34% Bearish
Price vs 50-day avg
−21% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.85% of float · ▼ -1.0% MoM · 22.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
71 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $3
vs 200-day avg -34% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Class A and Class B common stock outstanding 301,070,056 as of December 31, 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PROK
Prokidney Corp.
this stock
$402.09M -40.6% +1075.0% — 6.8%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
71
% held
15.9%
Net QoQ
+5.3M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
29
View
Short & Settlement
Short Interest Falling
Shares short
20.7M
Days to cover
22.4d
Change
-206.9K sh
View
Short Volume
Short vol %
85%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
24.8K
Value
$40.0K
As of
Jul 14, 2026
View
Off-Exchange
Off-exchange %
43.5%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-69.0M
EPS diluted
$-0.23
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
11
View
Proposed Sales
Value
$221.2K
Shares
81.9K
Filed
Nov 12, 2025
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
PROK -18.9% -17.9% -38.4% -13.6% -40.6%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -19.3% -22.4% -52.2% -17.6% -54.5%
Key facts CIK 1850270 CUSIP 74291D104 13F (30d) 70 filings 69 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)